

October 31, 2019

To

Listing Department,

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza.

Bandra Kurla Complex, Bandra (E),

MUMBAI -400 051

Company Code No. AUROPHARMA

To

The Corporate Relations Department

BSE LIMITED

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street.

MUMBAI -400 001

Company Code No. 524804

Dear Sir,

Sub: Board Meeting to consider the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2019.

We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 that a Meeting of the Board of Directors of the Company will be held on **Tuesday**, **November 12, 2019** to consider and approve inter alia, the following:

- 1. Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2019.
- 2. Payment of Interim Dividend, if any, for the financial year 2019-20.

Further to our letter dated September 26, 2019 informing the closure of Trading Window of the Company from October 1, 2019 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter ended September 30, 2019, we inform you that the Trading Window will remain closed up to November 14, 2019 and shall be re-opened on November 15, 2019.

Please take the information on record

Thanking you,

Yours faithfully, For AUROBINDO PHARMA LIMITED

B. Adi Reddy

Company Secretary

B. Re.



AUROBINDO PHARMA LIMITED

(CIN: L24239TG1986PLC015190)

PAN No. AABCA7366H